Percentage of Assured Money Vs. Total Potential Value in Pre-Commercial Stage Licensings, '92-'94
In our statistical review, we chart the variation, year by year, in the average amount of money guaranteed to the licenser of a pre-commercial stage product as a percentage of the total potential value of the deal. It's been falling.
You may also be interested in...
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.
As part of efforts to “renovate” its good clinical practice (GCP) framework, the International Council for Harmonisation has framed new overarching GCP principles that can be applied to diverse trial types and data sources.